Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Ruijin Hospital
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07504471CT.gov Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases | — | Recruiting | — | — | — |
NCT06571461CT.gov Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer | — | Not Yet Recruiting | — | — | — |
NCT05218889CT.gov Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | — | Recruiting | — | — | — |
NCT04808687CT.gov Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer | — | Unknown | — | — | — |
NCT03779464CT.gov Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas | — | Unknown | — | — | — |
NCT03777462CT.gov Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 | — | Unknown | — | — | — |
NCT03825328CT.gov A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC ) | — | Unknown | — | — | — |
NCT03636308CT.gov Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer | — | Unknown | — | — | — |
NCT03585062CT.gov Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | — | Terminated | — | — | — |
NCT02131493CT.gov S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT03869294CT.gov GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients | — | Completed | — | — | — |
NCT01781520CT.gov Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT01693419CT.gov S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT01811277CT.gov SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | — | Unknown | — | — | — |
NCT01074996CT.gov Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers | — | Unknown | — | — | — |
NCT00514163CT.gov GEM vs GEM+TS-1 for Advanced Pancreatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| S-1 (this asset) | Ruijin Hospital | Approved | B · 62 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for S-1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P4 | BB · 68 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | BB · 65 |
| Colorectal Neoplasm | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. S-1 in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/s-1-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →